PCOS affects 1 in 10 women of reproductive age, causing irregular periods, excess androgen levels, and ovarian cysts. It ...

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global ...

Cosmo Pharmaceuticals N.V. (and Glenmark Pharmaceuticals (Glenmark) announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi ...

Glenmark Pharmaceuticals receives UK approval for Winlevi, a groundbreaking topical acne treatment with unique mechanism of ...

Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects millions of women worldwide. One of the most ...

While unwanted chin hair can be frustrating, addressing the underlying hormonal imbalance is key to managing the issue ...

Polycystic Ovary Syndrome (PCOS) is influenced by chronic low-grade inflammation, affecting insulin sensitivity, hormonal ...

By definition, people who are intersex have genitals, chromosomes or reproductive organs that don't fit into the male or ...

Shanghai Yidi Biotechnology Co. Ltd. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to an androgen receptor targeting moiety via a linker reported ...

Dublin, Ireland and Mumbai, India and London, United Kingdom--(Newsfile Corp. - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") and Glenmark Pharmaceuticals Limited ...

Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSAReal-world evidence of PYLARIFY’s effectiveness in ...